Literature DB >> 30381415

To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia.

Joshua T Schiffer1,2, Charles A Schiffer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30381415      PMCID： PMC6278970          DOI： 10.3324/haematol.2018.201897

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  9 in total

1.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

Authors:  Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

2.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

3.  Moving treatment-free remission into mainstream clinical practice in CML.

Authors:  Timothy P Hughes; David M Ross
Journal:  Blood       Date:  2016-03-24       Impact factor: 22.113

4.  The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts.

Authors: 
Journal:  Blood       Date:  2013-04-25       Impact factor: 22.113

5.  The evolution of dasatinib dosage over the years and its relevance to other anticancer medications.

Authors:  Charles A Schiffer
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

6.  Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

Authors:  Kiran Naqvi; Elias Jabbour; Jeffrey Skinner; Musa Yilmaz; Alessandra Ferrajoli; Prithviraj Bose; Philip Thompson; Yesid Alvarado; Nitin Jain; Koichi Takahashi; Jan Burger; Zeev Estrov; Gautam Borthakur; Naveen Pemmaraju; Shilpa Paul; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2018-05-03       Impact factor: 6.860

7.  De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Authors:  Richard E Clark; Fotios Polydoros; Jane F Apperley; Dragana Milojkovic; Christopher Pocock; Graeme Smith; Jenny L Byrne; Hugues de Lavallade; Stephen G O'Brien; Tony Coffey; Letizia Foroni; Mhairi Copland
Journal:  Lancet Haematol       Date:  2017-05-26       Impact factor: 18.959

8.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

9.  Reduced tyrosine kinase inhibitor dose is predicted to be as effective as standard dose in chronic myeloid leukemia: a simulation study based on phase III trial data.

Authors:  Artur C Fassoni; Christoph Baldow; Ingo Roeder; Ingmar Glauche
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.